^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) +
    Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/04/2022
    Excerpt:
    Acute Lymphoblastic Leukemia...Other Recommended Regimens...Inotuzumab ozogamicins + mini-hyperCVD ± blinatumomabs (for B-ALL only) (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine)
    Secondary therapy:
    cytarabine; Mini-HCVD; vincristine; cyclophosphamide; methotrexate;